Skip to Content
Center for
Change lives. Change organizations. Change the world.
Follow us :
![[icon - facebook]](/sites/csi.gsb.stanford.edu/files/icon_img_f.gif "[icon - facebook]"){kind=icon}
![[icon - twitter]](/sites/csi.gsb.stanford.edu/files/icon_img_t.gif "[icon - twitter]"){kind=icon}
![[icon - LinkedIn]](/sites/csi.gsb.stanford.edu/files/LinkedIn.jpg "[icon - LinkedIn]"){kind=small}
Research: Undisclosed Pharma Contributions
Stanford Social Innovation Review, Fall 2011
In 2007, Eli Lilly and Company gave the National Alliance on Mental Illness (NAMI) $450,000 toward its Campaign for the Mind of America, which, if successful, could greatly expand the market for Lilly’s newest and most expensive psychiatric drugs.
Potential conflict of interest in the funding of health advocacy organizations (HAOs) by pharmaceutical companies is hard to suss out, because those relationships are mostly not made public. After doing a systematic analysis of the disclosure practices of HAOs, “I was very surprised at the large number of organizations that did not disclose” industry contributions, says Sheila Rothman, a professor at Columbia University’s Mailman School of Public Health.
Although there is no general legal requirement for companies to do so, as part of settlement agreements with the US ... Read more
Subscription Required
You must be a subscriber to read this SSIR article in its entirety.
Subscribe at SSIReview.org
You must be a subscriber to read this SSIR article in its entirety.
Subscribe at SSIReview.org
